The conference presentations provide incremental validation of EP-104GI's durability signal but do not release new data. The next binary catalyst is the Phase 2b interim data expected in December 2026 — monitor for top-line results which could significantly derisk the program.
Price Chart
Executive Summary
Eupraxia announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis have been accepted for presentation at the ACG and UEG medical conferences in October 2026. The presentations will highlight 52-week durability data on dysphagia improvement and histopathological features from the open-label dose-escalation portion. The company also disclosed that interim data from the Phase 2b placebo-controlled portion is expected in December 2026.
Key Facts
- Three abstracts from the Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis accepted at ACG (Oct 12) and UEG (Oct 18-19) conferences.
- Presentations include 52-week follow-up data on dysphagia and histopathological features from the open-label dose-escalation cohorts.
- Phase 2b placebo-controlled portion (120mg and 160mg doses) is recruiting; interim data expected December 2026.
- No new clinical data disclosed in the filing — only acceptance of previously generated data for conference presentation.
Financial Impact
No financial figures reported. Clinical-stage company with no revenue; impact is pipeline visibility and potential catalyst from December 2026 interim data.
Risk Factors
- Phase 2b interim data may fail to replicate open-label efficacy in a placebo-controlled setting.
- Clinical-stage biotech with no approved products; requires additional financing to complete development.
- Company previously restated financial statements, creating potential overhang.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006551 |
| Document: f6k_100926.htm | 0001171843-26-006551 |
| Document: 0001171843-26-006551-index-headers.html | 0001171843-26-006551 |
| Document: 0001171843-26-006551-index.html | 0001171843-26-006551 |
| Document: 0001171843-26-006551.txt | 0001171843-26-006551 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.85 (−9.75%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.85 (+1.18%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.85 (−8.18%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Aug 25, 2026 8w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.85 (+7.68%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.85 (+2.70%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.85 (+5.71%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.85 (+5.06%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.85 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers